Articles from Neuronetics

Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical tools
By Neuronetics · Via GlobeNewswire · January 29, 2025

Data selected for oral presentation reinforce previous findings on safety and efficacy
By Neuronetics · Via GlobeNewswire · October 14, 2024

Policy update increases access for millions covered by HCSC BlueCross BlueShield policies
By Neuronetics · Via GlobeNewswire · September 25, 2024

BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression
By Neuronetics · Via GlobeNewswire · September 19, 2024

Upgrades improve communication, streamline data management, and strengthen security
By Neuronetics · Via GlobeNewswire · September 16, 2024

NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives
By Neuronetics · Via GlobeNewswire · September 3, 2024

Celebrating milestones in patient care and practice enhancement through NeuroStar’s innovative training facility
By Neuronetics · Via GlobeNewswire · August 20, 2024

New initiative aims to provide information and resources for teen mental health amidst rising public health concerns
By Neuronetics · Via GlobeNewswire · August 1, 2024

Coverage criteria consistent with recent FDA clearance for NeuroStar TMS
By Neuronetics · Via GlobeNewswire · July 22, 2024

NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal
By Neuronetics · Via GlobeNewswire · July 11, 2024

Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental health
By Neuronetics · Via GlobeNewswire · July 10, 2024

The first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industry
By Neuronetics · Via GlobeNewswire · July 1, 2024

Early prediction of nonresponse abstract selected for oral presentation as a prestigious Top 4 Abstract at CTMSS 2024
By Neuronetics · Via GlobeNewswire · June 13, 2024

Policy change comes quickly after FDA clearance for NeuroStar TMS use in ages 15 and older
By Neuronetics · Via GlobeNewswire · May 15, 2024

The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance
By Neuronetics · Via GlobeNewswire · May 1, 2024

Lack of early symptom improvement is not predictive of final responder status
By Neuronetics · Via GlobeNewswire · April 10, 2024

NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and older
By Neuronetics · Via GlobeNewswire · March 25, 2024

MALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQSTIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced an expanded commercial partnership with Transformations Care Network ("TCN"), one of the nation's largest mental health care providers. Under the new agreement, Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment to TCN, increasing its NeuroStar TMS footprint and availability to patients.
By Neuronetics · Via GlobeNewswire · March 7, 2024

Advancements provide workflow efficiencies for NeuroStar® TMS providers
By Neuronetics · Via GlobeNewswire · February 12, 2024

Criteria Change Reduces Requirements for Treatment Accessibility
By Neuronetics · Via GlobeNewswire · February 6, 2024

New accessory for NeuroStar TMS reduces patient setup steps and improves efficiency for providers
By Neuronetics · Via GlobeNewswire · December 18, 2023

Technological advances reduce time and increase efficiency for MDD treatment
By Neuronetics · Via GlobeNewswire · December 4, 2023

New updates designed to advance practice efficiency and patient outcomes
By Neuronetics · Via GlobeNewswire · November 13, 2023

Policy Updates from Magellan and Two Additional Payors Increase Access for 3.2 Million Covered Lives
By Neuronetics · Via GlobeNewswire · November 9, 2023

Findings confirm strong correlation between the number of TMS treatment sessions completed and improvement in MDD
By Neuronetics · Via GlobeNewswire · October 16, 2023

Portal provides resources to raise awareness around mental health and suicide prevention
By Neuronetics · Via GlobeNewswire · September 12, 2023

Award Acknowledges Excellence in Digital Marketing Efforts
By Neuronetics · Via GlobeNewswire · August 21, 2023

New automated features elevate the standard of care for NeuroStar® Advanced Therapy practices
By Neuronetics · Via GlobeNewswire · August 14, 2023

Policy Updates Impact Nationwide Commercial Plans for 16.8 Million Covered Lives
By Neuronetics · Via GlobeNewswire · July 19, 2023

First International Approval for Expanded Indication and Certification for MT Cap and D-Tect™ Technologies
By Neuronetics · Via GlobeNewswire · July 17, 2023

Award Recognizes Efforts to Raise Awareness Around Non-Drug Depression Treatment
By Neuronetics · Via GlobeNewswire · July 11, 2023

The Company expands technology for patients with obsessive-compulsive disorder
By Neuronetics · Via GlobeNewswire · June 12, 2023

Lower Medication Requirement Helps Depression Patients Obtain Treatment Sooner
By Neuronetics · Via GlobeNewswire · May 26, 2023

Lowest satisfaction among medication users, highest for users of non-drug solution TMS Therapy
By Neuronetics · Via GlobeNewswire · May 23, 2023

The Company is recognized for its commitment to employees’ well-being
By Neuronetics · Via GlobeNewswire · May 15, 2023

Achievement demonstrates Company’s commitment to rigorous standards for safe and effective products
By Neuronetics · Via GlobeNewswire · May 8, 2023

Data highlights the Company’s commitment to advancing TMS and improving patient outcomes
By Neuronetics · Via GlobeNewswire · May 3, 2023

Campaign features patients’ experiences to support others with depression
By Neuronetics · Via GlobeNewswire · May 2, 2023

Strategic role strengthens NeuroStar® Advanced Therapy commercialization team
By Neuronetics · Via GlobeNewswire · May 1, 2023

UHC Medicare Advantage plans in NGS states expand access via NPPs
By Neuronetics · Via GlobeNewswire · April 28, 2023

BlueCross BlueShield of Mississippi Latest to Allow Non-Physician Practitioners to Prescribe TMS
By Neuronetics · Via GlobeNewswire · April 13, 2023

Fifth FDA clearance in less than two years offers greater connectivity and flexibility to improve the patient and provider experience
By Neuronetics · Via GlobeNewswire · April 6, 2023

Award recognizes NeuroStar for its significant contributions toward patient wellbeing
By Neuronetics · Via GlobeNewswire · March 16, 2023

United HealthCare Optum Reduces Barriers to TMS Eligibility for Depression Patients
By Neuronetics · Via GlobeNewswire · March 2, 2023

Company Launches a New Educational Campaign For Providers
By Neuronetics · Via GlobeNewswire · February 23, 2023

Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced Therapy
By Neuronetics · Via GlobeNewswire · February 21, 2023

New Senior Leadership Role Will Streamline Alignment of All Company Revenue-Generating Functions
By Neuronetics · Via GlobeNewswire · February 16, 2023

NGS MAC Allows Non-Physician Practitioners with Autonomy to Prescribe TMS
By Neuronetics · Via GlobeNewswire · February 10, 2023

Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety
By Neuronetics · Via GlobeNewswire · January 17, 2023

NeuroStar’s technology once again recognized as an effective non-drug treatment for patients
By Neuronetics · Via GlobeNewswire · December 5, 2022

Enhancements further establish the Company’s leadership position as the top transcranial magnetic stimulation therapy
By Neuronetics · Via GlobeNewswire · November 14, 2022

NeuroStar technology is acknowledged for its innovation and accessibility as a non-drug treatment for mental health
By Neuronetics · Via GlobeNewswire · October 31, 2022

Published and Proposed Medicare Coverage through CGS and NGS MACs Will Reduce Number of Medication Trials, Leading to Increased Eligibility for TMS
By Neuronetics · Via GlobeNewswire · October 25, 2022